

Clinicopathological and Molecular Markers in Metastasizing Ameloblastoma: A Systematic Review of Case Reports

¹Dr. Juan Fernando Buestán Zambrano, Graduate Student, School of Dentistry, University of Cuenca, Cuenca, Ecuador, South America.

²Dr. María de Lourdes Rodríguez Coyago, Titular Professor of Semiology and Diagnostic Clinic, School of Dentistry, University of Cuenca, Cuenca, Ecuador, South America.

Citation of this Article: Dr. Juan Fernando Buestán Zambrano, Dr. María de Lourdes Rodríguez Coyago, “Clinicopathological and Molecular Markers in Metastasizing Ameloblastoma: A Systematic Review of Case Reports .”, IJDSR – June - 2021, Vol. – 3, Issue - 3, P. No. 07-23.

Copyright: © 2021, Dr. Juan Fernando Buestán Zambrano, et al. This is an open access journal and article distributed under the terms of the creative commons attribution noncommercial License. Which allows others to remix, tweak, and build upon the work non commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Corresponding Author: Dr. Juan Fernando Buestán Zambrano, Graduate Student, School of Dentistry, University of Cuenca, Cuenca, Ecuador, South America.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Introduction

Ameloblastoma is a benign odontogenic tumour that is aggressive and localised in nature, listed as the first or second most prevalent odontogenic tumour and rarely tends to metastasis, but when it does, it receives the definition adopted by the WHO in 2017 of metastasizing ameloblastoma.

Materials and Methods

This systematic review of clinical case reports of metastasizing ameloblastoma from the last 10 years, collected from PubMed, Science Direct and Cochrane digital databases, aims to search for association between clinical/pathological and/or molecular parameters of ameloblastoma and its metastatic potential.

Results

The targeted search yielded 14 publications with a total of 18 clinical cases, which showed a mean age for diagnosis of metastasizing ameloblastoma of 46 years, with no gender predilection and a high probability of occurrence in the yellow Asian race, favouring a pattern of distant dissemination. The highest frequency of metastasis was associated with mandibular primary lesions diagnosed in young patients, and, the most frequently found variant was the multicystic solid type, follicular subtype; distant metastasis was the predominant form of presentation, with the lungs being the main target.

Conclusions

At the moment, there is nothing that can predict

metastatic potential in ameloblastoma. More standardised studies exploring the molecular terrain are needed, as this is a key and understudied factor.

Keywords

Ameloblastoma, metastasis, metastasizing.

Introduction

Ameloblastoma (AM) is a benign neoplasm of odontogenic epithelium originating from residual epithelial components (Molasses's and reduced enamel organ remains), basal cells of the epithelium of the jaws and of the epithelium of cysts and benign odontogenic tumours such as dentigerous cyst and odontoma respectively; characterised by slow growth, aggressive local behaviour and high recurrence¹⁻³. Despite being an infrequent pathology, representing 1% of all tumours in the head and neck region, with an estimated annual incidence of around 0.6 cases per million inhabitants, it is the first or second most prevalent odontogenic tumour in Latin America, varying according to the region⁴. A local study carried out at the Eugenio Espejo Hospital in the city of Quito, Ecuador, found ameloblastoma to be the most prevalent odontogenic tumour, followed by odontoma⁴; epidemiology concordant with references from Brazil⁵.

The latest edition of the WHO for odontogenic tumours reformulates the classification of this tumour into 4 subtypes according to location and histological variant: 1) conventional AM (solid/multicystic type) representing 80% of cases, 2) unicystic AM, representing 5-15% of cases, 3) extraosseous peripheral AM, with less than 1% of cases and 4) metastasizing ameloblastoma (MA). Additionally, conventional and unicystic AM present histological sub-variants: follicular, plexiform, desmoplastic, acanthomatous, basal cell, granular cell within the conventional ones; and luminal, intraluminal, and mural variants for the

unicystic forms⁶. Although conventional AM is the most prevalent and recurrent, metastatic ameloblastoma has demonstrated significant morbidity and mortality, especially in distant metastatic forms⁷. Indeed, after diagnosis of metastatic ameloblastoma to lung a medium survival of three years has been reported and a 5-year survival rate for the same entity of 37%⁸. There is little research on this unusual pathology, which clinically presents as a malignant tumour but histologically appears as a benign tumour; the systematic reviews that have been published so far on the subject focus on the clinical-demographic aspects of this tumour, and the impact of these factors on the survival of the tumour once it has developed⁶. To date, there are no systematic reviews that focus on the clinicopathological and especially molecular factors that allow prediction of the type of AM that will evolve to a metastatic phenotype; we need more research, with a high level of evidence, that provides more information on the clinicopathological and molecular factors that help predict the development of this clinicopathological entity of complex biology. Against this background, our aim is to present a systematic review of clinical case reports of metastasizing ameloblastoma (MA) published in the last 10 years. The results of this research will provide head and neck clinicians with better tools in the prognostic assessment of patients diagnosed with ameloblastoma.

Material and Methods

Peak Question

Is it possible to predict the metastatic potential of ameloblastoma by clinicopathological and/or molecular markers?

Eligibility or Inclusion Criteria and Data Extraction

Case reports and/or case series reporting clinical, pathological and/or molecular data on

metastasizing ameloblastoma, published from 2011 to 2020, were included for this review. From each selected study, the following clinical data were taken: age, sex, comorbidities, toxic habits, history of human papillomavirus (HPV) and Epstein Barr virus (EBV) infections, tumour size, tumour location and radiographic appearance. The pathological and molecular data recorded from each selected study corresponded to: histological variant and sub-variant of ameloblastoma, surgical margins, immuno-expression for MAPK (*RAS*, *BRAF*, *FGFR2*) and non-MAPK (*SMO*) oncogenes, proliferative marker Ki67, markers of inflammation such as *COX2*, markers of invasion such as metalloprotease (MMP) genes, tumour suppressors such as p53, and markers of epithelial-mesenchymal transition (E-cadherin, Syndican-1)^{6,9,10}.

Exclusion Criteria

Letters to the editor, review articles, association articles, systematic reviews, clinical trials and articles that do not focus on the subject matter. In addition, scientific papers in incomplete text or without access were excluded.

Search Strategy

Based on the *Preferred Reporting Items for Systematic Review and Meta-Analysis* (PRISMA)¹¹ guidelines, an electronic search was conducted in three digital databases, PubMed, Science Direct and Cochrane

for the collection of scientific articles published during the period 2011-2021, for which, MeSH terms were used in all fields¹², in order to maximise the search during the research. The search strategies defined for the databases described above were: *metastasizing* "AND" *ameloblastoma* OR *metastases* "AND" *ameloblastoma* "AND" *clinical and pathological markers* "OR" *molecular markers* "AND" case report. Only English language publications were considered, and duplicate articles in more than one database were considered only once.

Study Selection

14 case reports were selected from the last ten years that provided information on the different variables established in the present study. Figure 1 details in flow chart the stages of the search process, filtering by exclusion criteria, and selection of studies according to eligibility criteria. Table 1 shows a summary of the number of studies obtained and excluded by database used in this study.

Data Recording

The data were organised and processed in tables using Microsoft Excel 2010 software; statistical analysis was carried out by Info Stat software version 2018 of the National University of Cordoba, for which, a *p-value* of less than alpha error was considered significant, assuming as alpha a value equal to 0.05.

Figure 1: Flow chart showing the methodology used in the selection of studies for full analysis.




Table 1: Summary of the total number of studies obtained and filtered by scientific database used in the study.

Study	Reference Number	Number of clinical cases reported	Level of evidence and recommendation according to SIGN[13]
A case of ameloblastoma with extensive pulmonary metastasis survived for 14 years without treatment of the lung.	[14]	1	Level 3; Grade D recommendation
Malignant ameloblastoma (metastatic ameloblastoma) in the lung: 3 cases of misdiagnosis as primary lung tumour with a unique growth pattern.	[15]	3	Level 3; Grade D recommendation
Malignant ameloblastoma: a challenging diagnosis.	[16]	1	Level 3; Grade D recommendation
Malignant ameloblastoma metastasis to the neck - radiological and pathohistological dilemma.	[17]	1	Level 3; Grade D recommendation
Mandible ameloblastoma with lung metastasis: a rare case report.	[18]	1	Level 3; Grade D recommendation
Metastasizing Ameloblastoma with Localized Interstitial Spread in the Lung: Report of Two Cases.	[19]	2	Level 3; Grade D recommendation
Metastasizing Maxillary Ameloblastoma: Report of a Case with Molecular Characterization.	[20]	1	Level 3; Grade D recommendation
Multiple Organ Metastases from Ameloblastoma Detected by FDG PET/CT Imaging.	[21]	1	Level 3; Grade D recommendation
Pulmonary metastases from an Ameloblastoma: Case report and review of the literature.	[22]	1	Level 3; Grade D recommendation
Unicystic ameloblastoma metastasizing to multiple cervical lymph nodes.	[23]	1	Level 3; Grade D recommendation
Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature.	[24]	1	Level 3; Grade D recommendation
Ameloblastoma with varied sites of metastasis: Report of two cases and literature review.	[25]	2	Level 3; Grade D recommendation
Metastasizing Ameloblastoma e A peremial pathological enigma? Report of a case and review of literature.	[26]	1	Level 3; Grade D recommendation
Review of metastasizing (malignant) ameloblastoma (METAM): pattern of metastasis and treatment.	[8]	1	Level 2+; Grade C recommendation

Results

Demographic and Clinical Characteristics Associated with MA

Eighteen cases of metastasizing ameloblastoma (MA) were retrieved from a total of 14 published case reports on this pathological entity, and selected under the pre-established inclusion and exclusion criteria (Fig. 1) (Table 2). In our analysis, the metastatic tumour showed equal distribution in both sexes, with a mean age at diagnosis of 46 years and a clear predilection for the Asian yellow race. 77% of published cases reported mandibular location for the primary tumour, with the preferred site of metastasis being the lung, followed by cervical lymph nodes, and one case reported metastasis to multiple distant sites. The most common form of metastasis presentation was distant dissemination with 77.7% of the published cases, while loco-regional metastasis was the most infrequent form of MA manifestation (Table 3). Information on the diameter of the primary tumour was obtained in only 5 patients out of the 18 cases retrieved, with an average value of 3.5 cm for this variable. Regarding the radiographic appearance of the initial lesion, information was collected in only 8 of the 18 patients included in the study, with a clear predominance of radiolucent/hypodense multiloculated radiographic presentation and/or with irregular borders. In less than 25% of cases the presentation was uniloculated radiolucent, and only 12.5% of cases reported diffuse opacity based radiographic presentation (Table 3).

Regarding to the medical history of the patients, only 2 of the 18 cases admitted to the study provided information: in one patient a history of Alzheimer's

disease and advanced stage periodontal disease was recovered, in the second case a positive history was obtained for epithelial cancer and ischaemic heart disease; in no case was a history of toxic habits or infectious diseases such as HPV and EBV reported.

In regard to the dental history of the patients admitted to the study, 47.1% reported having received radical surgery in the first or second instance for the maxillofacial tumour diagnosed as ameloblastoma, compared to 52.9% who reported a history of conservative surgery for the same diagnosis. Of the 100% of patients analysed in this study, 44.4% reported a history of recurrent ameloblastoma, while 14.3% reported a history of third molar extraction (Table 3).

Given the data obtained with descriptive statistics, we asked ourselves whether clinical parameters such as age at diagnosis of the primary tumour, sex, ethnicity, location and treatment of the initial ameloblastoma influence the metastatic pattern of an MA. To answer this question, we related by contingency table the variable metastatic pattern with the different clinical-demographic parameters indicated. The hypothesis was tested by Pearson's Chi-square test, without obtaining a statistically significant association with any of the variables studied (Table 4). However, it is interesting to note that mandibular location, Asian/yellow and black race, age group under 30 years and conservative surgical approach to the initial tumour showed a higher probability of distant metastasis (Table 4); these data need to be confirmed with a larger sample size.

Table 3: Clinical-demographic characteristics of published cases of metastasizing ameloblastoma.

Variable	Number	Percentage
Sex		
Men	9	50
Women	9	50
Age at tumour diagnosis I		
< 30 years	10	55.6
Between 30 - 60 years old	6	33.3
> 60 years	2	11.1
Race/Ethnicity		
Asian Yellow	14	77.8
Black	2	11.1
Caucasian	2	11.1
Medical history		
Presence of comorbidities	2	100
Absence of comorbidities	0	0
Does not report	16 cases	
Tumour localization I		
Jaw	14	77.8
Maxilla	4	22.2
Radiographic appearance of tumour I		
Multilocular radiolucent	5	62.5
Unilocular radiolucent	2	25
Diffuse opaque lesion	1	12.5
Not report	11 cases	
Metastasis pattern		
Distant	14	77.8
Locoregional	4	22.2
History of Recurrence		
Present	8	44.4
Absent	10	55.6
Treatment of tumour I		
Radical surgical	8	47.1
Conservative surgical	9	52.9
Not report	1 case	

Note: Clinical cases that did not contribute information in the categories established by this study were not considered in the statistical analysis.

Table 4: Relationship between the pattern of metastasis and clinically important variables in cases diagnosed as MA.

Variable	Metastasis pattern		p-value
	Distant Cases (%)	Locoregional Cases (%)	
Age group according to tumour diagnosis I			
< 30 years	7 (38.9)	3 (16,6)	0,1
Between 30 - 60 years old	6 (33.3)	0 (0)	
> 60 years	1 (5.6)	1 (5.6)	
Sex	Cases (%)	Cases (%)	> 0,9
Man	7 (38.9)	2 (11.1)	
Woman	7 (38.9)	2 (11.1)	
Race/ethnicity	Cases (%)	Cases (%)	0,4
Asian yellow	11 (61)	3 (16.7)	
Black	2 (11.1)	0 (0)	
Caucasian	1 (5.6)	1 (5.6)	
Tumour localisation I	Cases (%)	Cases (%)	0,1
Jaw	10 (55.6)	4 (22.2)	
Maxilla	4 (22.2)	0 (0)	
Treatment of tumour I	Cases (%)	Cases (%)	0,5
Radical surgery	6 (35.3)	2 (11.7)	
Conservative surgery	8 (47,1)	1 (5.9)	

Note: Based on our data, the metastatic pattern shows no statistically significant association with clinical-demographic criteria associated with the primary tumour.

With the results obtained in the initial statistical analysis (Table 4), we asked ourselves whether the age at diagnosis of the primary tumour is a predictor of MA according to gender. To answer this question, we used a contingency table to relate the variable age group according to age at diagnosis of the primary tumour to the variable gender. (Table 5). The hypothesis was tested by Pearson's Chi-square test, with a significance level of 0.05. Although the difference was not statistically significant, it could be recognised that the probability of diagnosing an MA is higher when the primary tumour was detected before the age of 30, regardless of gender.

Pathological Features Associated with MA

Of the total number of patients admitted to the

study (N=18), the clinicopathological variant was reported in only 15 cases, with the conventional (solid/multicystic) type of ameloblastoma predominating in the series analysed. Less than 15% of the reported cases corresponded to the unicystic variant (Table 6).

Regarding the histopathological sub-variant of the primary tumour, only 13 cases provided this data, with a higher representation of the follicular subtype, with almost half of the documented clinical cases, followed by the plexiform subtype. Only one case was reported as acanthomatous AM, only one case as intraluminal and only one case as mixed (follicular/plexiform) ameloblastoma (Table 6).

None of the articles processed (N=14) provided information on the surgical margins of the primary tumour.

Table 5: Analysis of association between clinically important variables in MA with age at diagnosis of the primary tumour.

<i>Clinical/demographic aspects</i>	<i>Age category</i>			<i>p-value</i>
	<i>< 30 years</i>	<i>30 -60 years</i>	<i>> 60 years</i>	
	<i>No. of cases (%)</i>	<i>No. of cases (%)</i>	<i>No. of cases (%)</i>	
<i>Sex</i>				0,2
<i>Female</i>	5 (27.8)	4 (22.2)	0 (0)	
<i>Male</i>	5 (27.8)	2 (11.1)	2 (11.1)	

Note: The probability of occurrence of an MA is slightly higher when the diagnosis of the primary tumour occurs before the age of 30, irrespective of gender or sex.

Table 6: Pathological features of published cases of metastasizing ameloblastoma.

<i>Variable</i>	<i>Number</i>	<i>Percentage</i>
<i>Clinicopathological variant</i>		
<i>Conventional</i>	13	86.7
<i>Unicystic</i>	2	13.3
<i>Not report</i>	3 cases	
<i>Histological subtype</i>		
<i>Follicular</i>	6	46.2
<i>Plexiform</i>	4	30.8
<i>Other</i>	3	
<i>Not report</i>	5 cases	

Note: Clinical cases that did not contribute information in the categories established by this study were not considered in the statistical analysis.

Based on the data obtained by descriptive statistics, we asked ourselves whether there was an association between the metastatic pattern and the pathology of the primary tumour; to answer both questions we performed a categorical analysis by contingency table and Chi-square test. The statistical

analysis did not allow us to recognise a significant association between the variables studied; however, it is worth noting the greater probability of occurrence of an MA with a distant pattern given a primary tumour with a conventional variant (solid/multicystic) and follicular growth subtype (Table 7).

Table 7: Relationship between the pattern of metastasis and pathologically important variables in cases diagnosed as MA and recovered in this study.

Variable	Metastasis pattern		p- value
	Distant Cases (%)	Locoregional Cases (%)	
<i>Clinicopathological variant</i>			
Conventional	11 (73.3)	2 (13.3)	0,3
Unicystic	1 (6.7)	1 (6.7)	
<i>Histological subtype</i>			
Follicular	5 (38.5)	1 (7,7)	0,3
Other	4 (30.8)	3 (23)	

Note: None of the pathological parameters analysed showed significant association with the metastatic pattern of ameloblastoma. However, it is likely that by increasing the "N" we can more accurately assess the relationship between metastatic pattern and histological subtype.

Molecular Characteristics Associated with MA

Of the 18 clinical cases retrieved from the total number of articles selected, only 11 cases reported information on the molecular profile of the primary tumour, with wide heterogeneity of data and markers investigated. Table 8 shows that less than 10% of the reported MA cases had a molecular profile of the primary tumour positive exclusively for MAPK pathway genes such as BRAF. In 81% of the published cases, positivity was recovered for genes other than those comprising the MAPK pathway such as EGFR, p53, Ki67, Cytokeratins, EMA, TIF-1, HER2, p63, Wapsin A and PCK; in one case (9.1%)

positivity was reported for both MAPK and BRAF and non-MAPK genes (Table 8).

Given the results obtained in the descriptive statistics, we wondered whether a particular molecular profile can explain the pattern of metastasis in cases of ameloblastoma with this form of clinical presentation. To answer this question, we performed a categorical analysis by contingency table and Chi-square test, obtaining that the molecular profile does not affect the metastatic pattern of an ameloblastoma with this potential (Table 9). However, it is necessary to confirm these results with a larger number of clinical cases; additionally, it is necessary that each case of MA diagnosed is published with the molecular profile

looking for MAPK pathway genes and non-MAPK genes that have shown association with ameloblastoma and its prognosis such as *SMO*, p53-MM2,

metalloproteases, NOTCH pathway, Ki-67, and genes that promote epithelial mesenchymal transition such as *SLUG*, *TGF-B*, E-cadherin and Syndecan-1^{6,9,10}.

Table 8: Molecular characteristics in cases diagnosed and published as MA.

<i>Variable</i>	<i>No. of cases</i>	<i>Percentage</i>
<i>MAPK genes</i>	1	9.1
<i>Non-MAPK genes</i>	9	81.8
<i>Both markers</i>	1	9.1
<i>Uninformed</i>		

Note: Of the 18 clinical cases entered into the study, 7 cases did not report the molecular profile of the primary tumour

Table 9: Association by categorical analysis of the molecular profile of the primary tumour in reported cases of MA with the reported metastatic pattern.

<i>Metastasis pattern</i>	<i>Molecular profile of tumour I</i>			<i>p- value</i>
	<i>MAPK genes (%)</i>	<i>Non-MAPK genes (%)</i>	<i>Both markers (%)</i>	
<i>Distant</i>	1 (9.1)	7 (63.6)	0 (0)	0.2
<i>Locoregional</i>	0 (0)	2 (18.2)	1 (9.1)	

Note: Categorical analysis demonstrates no significant association between the molecular profile of the primary tumour and the metastatic pattern in patients with this diagnosis.

None of the published cases investigated, from a molecular point of view, the presence of cells with *stem cell* phenotype in the pathology of the primary tumour; an aspect that we consider important, as recent research has detected in ameloblastomas a subpopulation of epithelial cells with *stem-like* characteristics, classified as AM-EpiSCs LGR5⁺¹⁰.

Discussion

In 2011, thanks to the emblematic work of Hanahan and Weimberg, the phenotypes that characterise a malignant cell became known, one of

them being the capacity to metastasise locally or at a distance²⁷. This means that metastasis is cancer; however, the latest edition of the WHO on odontogenic tumours classified MA as a benign variant of ameloblastoma^{6,7}, and despite this, the prognosis of this pathological entity is not encouraging⁷. In view of this, we set out to determine by systematic review of clinical case reports published in the last 10 years, the association between clinicopathological and/or molecular factors and metastasizing ameloblastoma with a view to understanding its pathogenesis, and to

find possible predictors for this clinical entity with contradictory histology.

MA is a tumor of rare occurrence is a tumour of rare occurrence, with less than 1% incidence, being diagnosed as metastatic at the time of the primary lesion in 15% of cases, while in a high proportion this variant of ameloblastoma is diagnosed between 3 months to 24 years after the primary tumour, with an average latency time of 8.23 years⁷. The underlying mechanisms that would lead a benign tumour such as AM to metastasise are not fully understood; based on data from benign tumours of similar behaviour such as metastasising pleomorphic adenoma or benign fibrous cutaneous metastasising histiocytoma²⁸⁻³¹, it is hypothesised that incomplete removal of the primary tumour or a history of multiple surgical interventions for recurrent tumour favour haematogenous spread of tumour cells with consequent metastasis. However, some do not accept this theory, given the ability of the immune system to inactivate tumour cells present in the bloodstream by cell-mediated immune-dependent mechanisms^{7,32,33}. Praetorius in his 2009 review on malignant odontogenic tumours proposes the size and evolution of the primary tumour, mandibular location, repeated and incomplete surgical interventions, or a primary tumour treated with chemotherapy and radiotherapy, as possible clinical predictors of metastasis³⁴. "However, the underlying mechanism by which each of these factors influences the pathogenesis of MA remains to be elucidated."

In our series, MA showed no gender predilection, with a male to female ratio of 1:1. This finding is in agreement with the report of Luo et al.²²; although, other studies have reported a subtle male predominance of MA^{7,8,35}. The mean age at diagnosis of MA was 46 years, which is very close to that reported by Deepak et al. in their review, where the mean age was

42.62 years³⁵, and another study by Dissanayake et al. reported a mean age of 33.85 years⁸. When analysing the relationship between the age at diagnosis of the initial ameloblastoma or primary tumour and the appearance of metastases according to sex, we found that the possibility of diagnosing a metastatic ameloblastoma is 1.3 times higher when the primary tumour was detected before the age of 30 years, with no differences with respect to sex (Table 5), although the difference was not statistically significant, which may be due to a low sample size.

Regarding the clinical characteristics of the primary tumour in our series, 77.8% of the diagnosed metastasizing ameloblastomas had their primary located in the mandible, with a mandible/maxilla ratio of 4:1 (Table 4), coinciding with other reports that place the lower jaw as the site most involved by ameloblastoma^{8,23,36}. In fact, previous evidence suggests that the mandible is a possible predictor of MA³⁴.

In reference to the location of metastasis, the distant metastatic pattern accounted for 78.6% of the cases analysed (Table 3), with the lung being the site of greatest involvement, which is consistent with other reports^{7,17,35}. When relating the pattern of metastasis to the different eligible clinical-demographic variables, although no statistically significant association was obtained, markers such as mandibular location, early diagnosis of a primary AM, and yellow Asian race are associated with a higher probability of distant metastasis as a clinical presentation of an MA.

Histologically, in both the primary tumor and metastasis, the conventional variant (solid/multicystic) was the most prevalent in our series (Table 5), coinciding with the findings of Pandiar et al., and the WHO consensus [1, 35]. With respect to histological subtype, previous evidence indicates that the plexiform

or mixed (follicular/plexiform) variant commonly exhibits a higher likelihood of metastasis [33]. However, in our series the most prevalent histological subtype was follicular, accounting for 46.2% of cases, followed by the plexiform subtype with 30.8% representation (Table 6). These data coincide with the findings of Pandiar et al., and Ikemura et al., fact, Ikemura's group published in 1972 that, after evaluating 14 cases of metastatic ameloblastoma, 50% of the primary tumors presented the follicular type of growth [35, 37]. According to Pandiar and his group, the follicular variant histologically follows a growth pattern reminiscent of odontogenesis prior to morpho differentiation, with abundant bud-like structures [35]. They postulate that during surgical procedures these structures may detach and implant elsewhere, but other authors such as Kunze et al. dismiss this theory [33, 35].

With respect to the treatment scheme with which the primary tumour was approached, 53% of our series received a conservative surgical approach in the management of their initial AM, with a 1.1:1 ratio with respect to metastatic ameloblastomas with a history of radical surgery (Table 3). When we related the primary tumour treatment variable to the pattern of dissemination, we found that those metastatic tumours with a history of conservative surgical approach based on curettage of their primary tumour were more likely to have distant metastases, although the difference was not statistically significant (Table 4). It is possible that during surgery, even if it is radical and the first treatment option for conventional intraosseous ameloblastoma³⁸, tumour cells with a *stem* phenotype may be aspirated, causing seeding and generation of foci in other sites such as the lung. Indeed, Vorzimer and Perla reported the presence of tumour cylinders in the lumen of the bronchi of a patient with pulmonary metastasis of an

ameloblastoma in only one case published to date[39]. The route of dissemination of tumour cells in an AM is not entirely clear, according to Laughlin the main route of dissemination in an AM would be the haematogenous route, given the reported cases of MA in different sites such as bone, liver, brain, skin, as well as lung and lymph nodes⁴⁰.

According to Laughlin, one of the reasons why a benign slow-growing tumor such as ameloblastoma might demonstrate a metastatic phenotype is its recurrent behaviour, favoured by incomplete and inadequate removal of the primary tumour by curettage, radiotherapy and chemotherapy[40]. In our study, less than half of the cases of MA had a history of recurrence (table 3), which is consistent with the results of Hosalkar et al. in their study, about a quarter of the cases of MA had a history of recurrence[7]. When we related the pattern of metastasis to the history of recurrence in MA we did not obtain a statistically significant association, implying that recurrence cannot be considered a predictor of metastasis in ameloblastoma. This conclusion is supported by several clinical case reports on metastatic ameloblastoma without a history of recurrence^{8,15,17,23-26}.

Regarding the molecular characteristics associated with MA, 81.8% of the metastatic tumours had a history of primary tumour positivity for non-MAPK pathway genes (Table 8), some of them such as p63 and high expression for Ki-67. This is similar to a review by Anjali et al. in which about 5 cases of report positivity for these genes⁴¹. When relating the molecular profile of the primary tumour to the pattern of metastasis, it was found that the probability of diagnosing an ameloblastoma with distant metastasis is higher if its primary tumour associated positivity for non-MAPK genes (Table 9), although the difference was

not statistically significant, most likely a result of the low number of reported cases. No studies with this type of analysis were found to contrast our results.

The weaknesses of our study are based on limited evidence regarding the clinical history of each case, as well as scarce or poor information on the primary lesion, its detailed radiographic appearance and its size. Likewise, with regard to the molecular characteristics, the lack of homogeneity between the different cases does not allow us to create a pattern of association between the different genes and the probability of metastasis of an ameloblastoma. In view of these limitations, we suggest that every case published on MA should contain a complete medical and odontostomatological history, with emphasis on the search for comorbidities, toxic, sexual and dietary habits, and a history of periodontal disease, as several studies have proposed smoked and chewed tobacco, chronic alcohol consumption, viral and fungal infections and chronic periodontitis as risk factors for oral cancer⁴²⁻⁴⁵, in addition, another clinical factor that has been shown to be a key factor in carcinogenesis is obesity, and we therefore recommend that the body mass index of each patient should be reported in every case published on MA, as the pathogenic mechanism by which obesity may promote the progression of a malignant tumour has recently been published⁴⁶. For all these reasons, we believe that a complete anamnesis could provide us with additional data of importance in the prognosis of an ameloblastoma; additionally, a detailed description of the primary lesion in terms of size and radiographic features, as well as homogeneity in terms of molecular markers will provide us with a better scenario for predicting the biological behaviour of an AM; and with respect to the molecular profile of this tumour, we recommend that every published case of MA

should report the association with MAPK genes (*RAS*, *BRAF*, *FGFR2*), and non-MAPK genes such as *SMO*, p53, Ki67, p63, plus markers of epithelial-mesenchymal transition and *stem* phenotype cells such as AM-EpiSCs/LGR5+. This since molecular biology studies have recognised two different genetic pathways exacerbated in ameloblastomas, as 90% of these tumours show mutations in genes of the MAPK (mitogen-activated protein kinase) pathway, of which the *BRAF* oncogene has been recognised as activated in 63% of ameloblastomas as a product of a point mutation V600E (change of valine to glutamate at codon 600); while 16-39% of ameloblastomas associate activating mutations in non-MAPK pathway genes (Hedgehog and WNT/beta-catenin pathways) such as *SMO* (G protein-coupled receptor and effector signalling component of the SHH pathway)^{6,8,9}. The causes that would lead to the activation of these oncogenes are not fully understood; limited evidence from descriptive studies based on molecular pathology demonstrates the possible involvement of tobacco⁴⁷, viruses such as HPV and EBV in the aetiopathogenesis of AM⁴⁸⁻⁵⁰, and recently a subpopulation of epithelial cells with the ability to co-express the *LGR5* marker and stem phenotype genes was reported in samples of solid ameloblastomas with follicular, mixed and desmoplastic subvariants, termed AM-EpiSCs LGR5+. The *LGR5* marker is a G protein-coupled receptor with leucine-rich repeats, a member of the LGR family of proteins, and has been identified as a marker of *stem* cells as well as *cancer stem cells* (CSCs) in several cancer types.

Functionally, *LGR5* has been shown to promote epithelial-mesenchymal transition in hepatocellular carcinoma, colon cancer and glioma, and is associated with poor survival in glioma patients. This subpopulation of AM-SCs-LGR5+ cells have been

shown to be functionally more adept at forming 3D spheroids and 3D human tumour organoids, which reproduced the histopathological features of different subtypes of solid ameloblastoma. Additionally, *in vitro* resistance of these cells to the BRAFV600E inhibitor (vemurafenib) has been reported, playing a key role in the pathogenesis and recurrence of AM¹⁰. Based on this background, we consider it necessary to investigate this cell subtype in the pathophysiology of metastasizing ameloblastoma.

Conclusions

MA is a very rare pathology that has been, surprisingly, reclassified as benign in the latest WHO consensus of 2017 for odontogenic tumours. Its diagnosis is approached in a retrospective manner on primary AM and its prediction is, for the moment, impossible given the scarcity of homogeneity in the clinical cases published on the MA entity, with respect to clinical, pathological and molecular criteria. Regarding the latter, there is a wide heterogeneity in the markers studied.

Based on the results obtained in the present study, it is likely that an early initial diagnosis (< 30 years) of AM, yellow Asian race, mandibular location, conventional variant (solid/multicystic), and follicular subtype of growth are possible predictors of metastatic behaviour in benign slow-growing tumours such as AM. Our findings also lead us to doubt the predictive potential that has been assigned to factors such as history of recurrence and type of surgical approach in the primary tumour or initial AM. Regarding the molecular profile as a candidate predictor of MA we have no literature to support our findings, therefore, the possible impact of non-MAPK genes in the pathogenesis of MA is inconclusive.

Further studies with a full clinicopathological report are needed to corroborate our findings.

Acknowledgements

To our patients for giving us the opportunity to learn.

References

1. El-Naggar A, Chan J, Grandis J, Takata T SP. WHO Classification of Head and Neck Tumours. *Int Agency Res Cancer*. 2017;4.
2. Small IA, Waldron CA. Ameloblastomas of the jaws. *Oral Surgery, Oral Med Oral Pathol*. 1955 Mar;8(3):281–97. Available from: <https://linkinghub.elsevier.com/retrieve/pii/0030422055903509>
3. Hong J, Yun P-Y, Chung I-H, Myoung H, Suh J-D, Seo B-M, et al. Long-term follow up on recurrence of 305 ameloblastoma cases. *Int J Oral Maxillofac Surg*. 2007 Apr;36(4):283–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0901502706004942>
4. Córdova Alvarez M, Benenaula Bojorque J. PREVALENCIA DE TUMORES BENIGNOS DE ORIGEN ODONTOGÉNICO EN PACIENTES ATENDIDOS EN EL HOSPITAL EUGENIO ESPEJO DURANTE LOS AÑOS 2011 A 2016. *Universidad Central del Ecuador*. 2017; Available from: <http://www.dspace.uce.edu.ec/handle/25000/12704>
5. De Medeiros WKD, Da Silva LP, Pedro-Paulo-De AS, Pinto LP, De Souza LB. Clinicopathological analysis of odontogenic tumors over 22 years period: Experience of a single center in northeastern Brazil. *Med Oral Patol Oral y Cir Bucal*. 2018;23(6):e664–71. <https://doi.org/10.4317/medoral.22618>

6. Soluk-Tekkeşin M, Wright JM. The world health organization classification of odontogenic lesions: A summary of the changes of the 2017 (4th) edition. *Turk Patoloji Derg.* 2018;34(1):1–18. <https://doi.org/10.5146/tjpath.2017.01410>
7. Hosalkar R, Saluja TS, Swain N, Singh SK. Prognostic evaluation of metastasizing ameloblastoma: A systematic review of reported cases in literature. *J Stomatol Oral Maxillofac Surg.* 2021;122(2):192–8. Available from: <https://doi.org/10.1016/j.jormas.2020.07.001>
8. Dissanayake RKG, Jayasooriya PR, Siriwardena DJL, Tilakaratne WM. Review of metastasizing (malignant) ameloblastoma (METAM): Pattern of metastasis and treatment. *Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology.* 2011;111(6):734–41. Available from: <http://dx.doi.org/10.1016/j.tripleo.2010.12.018>
9. Abdel-Aziz A, Amin MM. EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: Possible role in local recurrence. *Diagn Pathol.* 2012;7(1). <https://doi.org/10.1186/1746-1596-7-14>
10. Brown NA, Betz BL. Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. *Biomark Cancer.* 2015;7s2:BIC.S29329. <https://doi.org/10.4137/bic.s29329>
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* 2009;6(7). <https://doi.org/10.1371/journal.pmed.1000097>
12. Pinillo León AL, Cañedo Andalia R. El MeSH: Una herramienta clave para la búsqueda de información en la base de datos Medline. Vol. 13, Acimed. 2005. p. 1–15. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352005000200006
13. Petrisor BA, Keating J, Schemitsch E. Grading the evidence: Levels of evidence and grades of recommendation. *Injury.* 2006;37(4):321–7. <https://doi.org/10.1016/j.injury.2006.02.001>
14. Ikai A, Suzuki S, Hayashi K. A case of ameloblastoma with extensive pulmonary metastasis survived for 14 years without treatment of the lung. *J Oral Maxillofac Surgery, Med Pathol.* 2016;28(2):138–42. Available from: <http://dx.doi.org/10.1016/j.ajoms.2015.09.004>
15. Bi R, Shen L, Zhu X, Xu X. Malignant ameloblastoma (metastatic ameloblastoma) in the lung: 3 cases of misdiagnosis as primary lung tumor with a unique growth pattern. *Diagn Pathol.* 2015;10(1):1–6. Available from: <http://dx.doi.org/10.1186/s13000-015-0367-0>
16. Salami A, Ezenkw U, Salami M, Ajani M, Okolo C. Malignant ameloblastoma: a challenging diagnosis. *Autops Case Reports.* 2018;8(4). <https://doi.org/10.4322/acr.2018.043>
17. Golubović M, Petrović M, Jelovac DB, Nenezić DU, Antunović M. Metastaza malignog ameloblastoma na vratu - Radiološka i patohistološka dilema. *Vojnosanit Pregl.* 2012;69(5):444–8. <https://doi.org/10.2298/VSP1205444G>
18. Yang R-N, Wang X-S, Ren J, Xie Y-F, Zhou D, Ge D-F, et al. Mandible ameloblastoma with lung metastasis: a rare case report. *Int J Clin Exp Pathol.* 2015;8(6):6793–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26261564>
19. Chou YH, Jhuang JY, Chang MH, Huang WC, Hsieh MS. Metastasizing ameloblastoma with localized interstitial spread in the lung: Report of

- two cases. *Int J Surg Pathol.* 2014;22(4):343–6. <https://doi.org/10.1177/1066896913491321>
20. Rotellini M, Maggiore G, Trovati M, Saraceno MS, Franchi A. Metastasizing Maxillary Ameloblastoma: Report of a Case with Molecular Characterization. *J Oral Maxillofac Res.* 2016;7(1):1–7. <https://doi.org/10.5037/jomr.2016.7105>
21. Niu N, Chen L, Liu Y, Li F. Multiple organ metastases from ameloblastoma detected by FDG PET/CT imaging. *Clin Nucl Med.* 2013;38(12):1009–11. Available from: <http://dx.doi.org/10.1097/RLU.0b013e3182a7597f>
22. Luo DY, Feng CJ, Guo JB. Pulmonary metastases from an Ameloblastoma: Case report and review of the literature. *J Cranio-Maxillofacial Surg.* 2012;40(8):e470–4. Available from: <http://dx.doi.org/10.1016/j.jcms.2012.03.006>
23. Noguchi K, Kishimoto H, Yamanegi K, Moridera K, Takaoka K, Urade M. Unicystic ameloblastoma metastasizing to multiple cervical lymph nodes. *J Surg Case Reports.* 2013;2013(5):rjt033–rjt033. <https://doi.org/10.1093/jscr/rjt033>
24. Amzerin M, Fadoukhair Z, Belbaraka R, Iraqui M, Boutayeb S, M'Rabti H, et al. Metastatic ameloblastoma responding to combination chemotherapy: Case report and review of the literature. *J Med Case Rep.* 2011;5(1):491. Available from: <http://www.jmedicalcasereports.com/content/5/1/491>
25. Lin Y, He JF, Li ZY, Liu JH. Ameloblastoma with varied sites of metastasis: Report of two cases and literature review. *J Cranio-Maxillofacial Surg.* 2014;42(5):1–4. Available from: <http://dx.doi.org/10.1016/j.jcms.2013.10.010>
26. Jayaraj G, Sherlin HJ, Ramani P, Premkumar P, Natesan A, Ramasubramanian A, et al. Metastasizing Ameloblastoma - A perennial pathological enigma? Report of a case and review of literature. *J Cranio-Maxillofacial Surg.* 2014;42(6):772–9. Available from: <http://dx.doi.org/10.1016/j.jcms.2013.11.009>
27. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011;144(5):646–74. Available from: <http://dx.doi.org/10.1016/j.cell.2011.02.013>
28. Patton KT, Cheng L, Papavero V, Blum MG, Yeldandi A V., Adley BP, et al. Benign metastasizing leiomyoma: Clonality, telomere length and clinicopathologic analysis. *Mod Pathol.* 2006;19(1):130–40.
29. Knight J, Ratnasingham K. Metastasizing pleomorphic adenoma: Systematic review. *Int J Surg [Internet].* 2015;19:137–45. Available from: <http://dx.doi.org/10.1016/j.ijsu.2015.04.084>
30. Doyle LA, Fletcher CDM. Metastasizing “Benign” Cutaneous Fibrous Histiocytoma. *Am J Surg Pathol.* 2013 Apr;37(4):484–95. Available from: <https://journals.lww.com/00000478-201304000-00002>
31. Barnaś E, Raś R, Skręt-Magierło J, Wesecki M, Filipowska J, Książek M, et al. Natural history of leiomyomas beyond the uterus. *Medicine (Baltimore).* 2019;98(25):e15877. Available from: <https://doi.org/10.1097/MD.00000000000015877>
32. Houston G, Davenport W, Keaton W, Harris S. Malignant (metastatic) ameloblastoma: Report of a case. *J Oral Maxillofac Surg.* 1993;51(10):1152–5. Available from: [http://dx.doi.org/10.1016/S0278-2391\(10\)80458-6](http://dx.doi.org/10.1016/S0278-2391(10)80458-6)

33. Kunze E, Donath K, Luhr HG, Engelhardt W, De Vivie R. Biology of Metastasizing Ameloblastoma. *Pathol Res Pract.* 1985;180(5):526–35. Available from: [http://dx.doi.org/10.1016/S0344-0338\(85\)80017-0](http://dx.doi.org/10.1016/S0344-0338(85)80017-0)
34. Praetorius F. Malignant odontogenic tumours. *Surg Pathol head neckodontogenic tumours. In: Barnes L, editor 3rd ed. New York:Informa Healthcare;* 2009;12902.<https://www.routledge.com/Surgical-Pathology-of-the-Head-and-Neck/Barnes/p/book/9780849390234>.
35. Pandiar D, Anand R, Kamboj M, Narwal A, Shameena PM, Devi A. Metastasizing Ameloblastoma: A 10 Year Clinicopathological Review with an Insight Into Pathogenesis. *Head Neck Pathol.* 2021 Jan 4; Available from: <http://link.springer.com/10.1007/s12105-020-01258-5>
36. Van Dam SD, Unni KK, Keller EE. Metastasizing (malignant) ameloblastoma: Review of a unique histopathologic entity and report of Mayo Clinic experience. *J Oral Maxillofac Surg.* 2010;68(12):2962–74. Available from: <http://dx.doi.org/10.1016/j.joms.2010.05.084>
37. Ikemura K. AMELOBLASTOMA OF THE MANDIBLE WITH METASTASIS TO THE LUNGS AND LYMPH NODES. *Cancer.* 1972;29:930–40. [https://doi.org/10.1002/1097-0142\(197204\)29:4<930::aid-cnrc2820290439>3.0.co;2-#](https://doi.org/10.1002/1097-0142(197204)29:4<930::aid-cnrc2820290439>3.0.co;2-#)
38. Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. *Oral Dis.* 2018;24(3):307–16. <https://doi.org/10.1111/odi.12646>
39. Vorzimer J, Perla D. AN INSTANCE OF ADAMANTINOMA OF THE JAW WITH METASTASES TO THE RIGHT LUNG. *Am J Pathol.* 1932;8. <https://pubmed.ncbi.nlm.nih.gov/19970030/>
40. LAUGHLIN EH. Metastasizing Ameloblastoma. *Cancer.* 1989;64:776–80. [https://doi.org/10.1002/1097-0142\(19890801\)64:3<776::aid-cnrc2820640335>3.0.co;2-8](https://doi.org/10.1002/1097-0142(19890801)64:3<776::aid-cnrc2820640335>3.0.co;2-8)
41. Ganjre AP, Sarode G, Sarode S. Molecular characterization of metastasizing ameloblastoma: A comprehensive review. *J Cancer Res Ther.* 2018;15(3):455–62. <https://doi.org/10.4103/jcrt.JCRT>
42. Sanjaya PR, Gokul S, Gururaj Patil B, Raju R. Candida in oral pre-cancer and oral cancer. *Med Hypotheses.* 2011;77(6):1125–8. Available from: <http://dx.doi.org/10.1016/j.mehy.2011.09.018>
43. Hübbers CU, Akgül B. HPV and cancer of the oral cavity. *Virulence.* 2015;6(3):244–8. Available from: <https://doi.org/10.1080/21505594.2014.999570>
44. Rischin D, MacCallum P. Overview of Advances in Head and Neck Cancer. *J Clin Oncol.* 2015;33. Available from: <https://doi.org/10.1200/JCO.2017>.
45. Shaikh MH, McMillan NAJ, Johnson NW. HPV-associated head and neck cancers in the Asia Pacific: A critical literature review & meta-analysis. *Cancer Epidemiol.* 2015;39(6):923–38. Available from: <https://doi.org/10.1016/j.canep.2015.09.013>
46. Benaiges E, Ceperuelo-Mallafre V, Madeira A, Bosch R, Núñez-Roa C, Ejarque M, et al. Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity. *Cell Oncol.* 2021. Available from: <https://doi.org/10.1007/s13402-021-00597-x>

47. Guan P, Wong SF, Lim JQ, Ng CCY, Soong PL, Sim CQX, et al. Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. *J Dent Res.* 2019;98(6):652–8. Available from: <https://doi.org/10.1177/0022034519837248>
48. Namin AK, Azad TM, Eslami B, Sarkarat F, Shahrokhi M, Kashanian F. A study of the relationship between ameloblastoma and human papilloma virus. *J Oral Maxillofac Surg.* 2003;61(4):467–70. Available from: <https://doi.org/10.1053/joms.2003.50011>
49. Kahn MA. Ameloblastoma in young persons: A clinicopathologic analysis and etiologic investigation. *Oral Surgery, Oral Med Oral Pathol.* 1989;67(6):706–15. Available from: [https://doi.org/10.1016/0030-4220\(89\)90013-](https://doi.org/10.1016/0030-4220(89)90013-)
50. Fujita S, Shibata Y, Takahashi H, Tsuda N, Okabe H. Latent infection with Epstein-Barr virus in odontogenic disorders: Comparison among ameloblastoma, dentigerous cyst and odontogenic keratocyst. *Pathol Int.* 1997;47(7):449–53. Available from: <https://doi.org/10.1111/j.1440-1827.1997.tb04523.x>